InMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to discovering and advancing cannabinoid-based therapeutic solutions. Their primary drug candidate, INM-755, a cannabinol topical cream, is currently progressing through its second Phase I clinical trial for individuals suffering from epidermolysis bullosa. The company's pipeline also includes INM-088, which is undergoing preclinical investigations for glaucoma, and INM-405, under development for pain relief. Beyond these specific projects, InMed explores cannabinoid-derived treatments for a diverse array of illnesses, particularly in the dermatological and ophthalmic fields. The firm is also involved in crucial IND-enabling pharmacology and preclinical toxicology assessments, and it leverages IntegraSyn, an integrated biosynthesis manufacturing approach, to produce pharmaceutical-quality cannabinoids. A research partnership with BayMedica Inc. supports the creation and testing of innovative cannabinoid therapeutics. Established in 1981, the company adopted its current name in October 2014, previously operating as Cannabis Technologies Inc., and maintains its headquarters in Vancouver, Canada.